Results 101 to 110 of about 11,407 (242)

Biosimilars in Gynecologic Cancers: Basic Principles and New Horizons

Frontiers in Bioscience-Elite
Biological therapies have transformed cancer treatment by targeting the molecular mechanisms involved in carcinogenesis. However, higher costs, limited accessibility, and supply chain disruptions—such as those caused by COVID-19 in recent years ...
Mariem Galuia, Azhar Hussain, Sarfraz Ahmad   +2 more
doaj   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, Volume 101, Issue 7, Page 1359-1369, July 2026.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

The role of biosimilars in value-based oncology care

, 2018
Kashyap B Patel,1 Luiz H Arantes Jr,2 Wing Yu Tang,3 Selwyn Fung4 1Carolina Blood and Cancer Care, Rock Hill, SC, USA; 2Biosimilars Global Medical Affairs, Pfizer Essential Health, Pfizer Inc.
Patel KB, Tang WY, Arantes Jr LH, Fung S
core  

Investigating the Effect of Tumour Necrosis Factor Antagonist on Olfaction

Clinical Otolaryngology, Volume 51, Issue 4, Page 504-511, July 2026.
ABSTRACT Objectives Tumour Necrosis factor antagonists is a potent anti‐inflammatory medication and has shown to improve olfactory function in murine models. The primary aim was to determine the effect of TNF antagonists on olfactory performance in humans.
Andreas Espehana, George Macfarlane, Elizabeth Mairenn Garden, Liam Lee, Gabija Klyvyte, Lavandan Jegatheeswaran, Rebecca Davies, Carl Philpott   +7 more
wiley   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5527-5541, July 2026.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source

Biosimilars are coming: ready or not [PDF]

, 2018
Biosimilars have had a sizeable impact on the availability and use of biologic medicines in Australia, particularly those prescribed for supportive care in oncology or to treat inflammatory diseases.
Zalcberg, J
core   +1 more source

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background HER2 (ERBB2) gene mutations are associated with poor prognosis in non‐small cell lung cancer (NSCLC). It is important to identify patients with HER2‐mutant (HER2m) NSCLC, as new targeted treatment options are emerging. However, HER2 testing in clinical practice varies across regions, and real‐world data on HER2m NSCLC are limited ...
Didier Debieuvre, Pauline Macouillard, Xavier Quantin, Mehmet Berktas, Nicolas Girard, Clarisse Audigier‐Valette, Thomas Filleron, Stefania Musilli, Lise Bosquet, Maurice Pérol   +9 more
wiley   +1 more source

What role for real-world evidence in market access of biosimilars?

Frontiers in Pharmacology
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars.
Steven Simoens, Catherine M. Lockhart, Delphine F. Courmier   +2 more
doaj   +1 more source

Bilateral Avascular Necrosis of the Femoral Heads in Ankylosing Spondylitis Requiring Staged Total Hip Arthroplasty: A Case Report of Diagnostic and Therapeutic Challenges

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Ankylosing spondylitis (AS) is a chronic immune‐mediated inflammatory arthropathy primarily affecting the axial skeleton but may involve peripheral joints, particularly the hips. Avascular necrosis (AVN) of the femoral head represents a severe, underrecognized complication whose pathogenesis in AS is multifactorial—encompassing disease ...
Syeda Simrah Shah, Muhammad Ahsan, Tehreem Farooq, Mirza Daniyal Baig, Mirza Mohammad Ali Baig, Mohammed Hammad Jaber Amin   +5 more
wiley   +1 more source

Is Australia ready for biosimilars?

, 2014
The biosimilars market is potentially the single fastest growing pharmaceutical sector with an estimated worth of US$67bn in global sales by 2020. This market generally refers to larger molecule, biological, protein-based pharmaceuticals which have lost
Hepworth, Julie, Lim, David, Nissen, Lisa   +2 more
core